Patient cohort
| . | Total . | No GVHD . | Limited GVHD . | Severe GVHD . |
|---|---|---|---|---|
| Patients | 39 | 11 | 7 | 21 |
| Sex | ||||
| Female | 13 | 4 | 2 | 7 |
| Male | 26 | 7 | 5 | 14 |
| Sex (donor -> patient) | ||||
| f -> f | 12 | 3 | 2 | 7 |
| f -> m | 22 | 4 | 5 | 13 |
| m -> f | 1 | 1 | 0 | 0 |
| m -> m | 4 | 3 | 0 | 1 |
| Relation to donor | ||||
| Unrelated donor | 28 | 6 | 6 | 16 |
| Related donor | 11 | 5 | 1 | 5 |
| Disease | ||||
| AML | 13 | 2 | 3 | 8 |
| B-ALL | 1 | 0 | 1 | 0 |
| CLL | 3 | 1 | 0 | 2 |
| CML | 3 | 2 | 0 | 1 |
| MDS | 7 | 2 | 1 | 4 |
| MM | 8 | 2 | 1 | 5 |
| MPN | 1 | 0 | 0 | 1 |
| t-MN | 1 | 1 | 0 | 0 |
| T-ALL/LBL | 1 | 1 | 0 | 0 |
| T-NHL | 1 | 0 | 1 | 0 |
| Donor/recipient HLA type | ||||
| A∗01:01 | 22 | 7 | 2 | 13 |
| A∗02:01 | 22 | 9 | 5 | 8 |
| A∗03:01 | 16 | 3 | 3 | 10 |
| B∗07:02 | 28 | 9 | 5 | 14 |
| B∗08:01 | 23 | 5 | 3 | 15 |
| C∗07:01 | 25 | 6 | 3 | 16 |
| C∗07:02 | 28 | 9 | 5 | 14 |
| HLA matching | ||||
| 10/10 | 4 | 1 | 2 | 1 |
| 10/12 | 4 | 1 | 0 | 3 |
| 11/12 | 11 | 1 | 1 | 9 |
| 12/12 | 20 | 4 | 8 | 8 |
| . | Total . | No GVHD . | Limited GVHD . | Severe GVHD . |
|---|---|---|---|---|
| Patients | 39 | 11 | 7 | 21 |
| Sex | ||||
| Female | 13 | 4 | 2 | 7 |
| Male | 26 | 7 | 5 | 14 |
| Sex (donor -> patient) | ||||
| f -> f | 12 | 3 | 2 | 7 |
| f -> m | 22 | 4 | 5 | 13 |
| m -> f | 1 | 1 | 0 | 0 |
| m -> m | 4 | 3 | 0 | 1 |
| Relation to donor | ||||
| Unrelated donor | 28 | 6 | 6 | 16 |
| Related donor | 11 | 5 | 1 | 5 |
| Disease | ||||
| AML | 13 | 2 | 3 | 8 |
| B-ALL | 1 | 0 | 1 | 0 |
| CLL | 3 | 1 | 0 | 2 |
| CML | 3 | 2 | 0 | 1 |
| MDS | 7 | 2 | 1 | 4 |
| MM | 8 | 2 | 1 | 5 |
| MPN | 1 | 0 | 0 | 1 |
| t-MN | 1 | 1 | 0 | 0 |
| T-ALL/LBL | 1 | 1 | 0 | 0 |
| T-NHL | 1 | 0 | 1 | 0 |
| Donor/recipient HLA type | ||||
| A∗01:01 | 22 | 7 | 2 | 13 |
| A∗02:01 | 22 | 9 | 5 | 8 |
| A∗03:01 | 16 | 3 | 3 | 10 |
| B∗07:02 | 28 | 9 | 5 | 14 |
| B∗08:01 | 23 | 5 | 3 | 15 |
| C∗07:01 | 25 | 6 | 3 | 16 |
| C∗07:02 | 28 | 9 | 5 | 14 |
| HLA matching | ||||
| 10/10 | 4 | 1 | 2 | 1 |
| 10/12 | 4 | 1 | 0 | 3 |
| 11/12 | 11 | 1 | 1 | 9 |
| 12/12 | 20 | 4 | 8 | 8 |
Patients were selected based on expression of common HLAs and reported GVHD or disappearance of hematopoietic patient cells after DLI.
AML, acute myeloid myeloma; B-ALL, B-cell acute lymphoblastic leukemia, CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPN, myeloproliferative neoplasm; T-ALL/LBL, T-lymphoblastic leukemia/lymphoma; t-MN, therapy-related myeloid neoplasm; T-NHL, T-cell non-Hodgkin lymphoma.